文献速递泌尿男性生殖肿瘤

既往免疫检查点抑制剂治疗后转移性肾细胞癌中伊匹木单抗联合纳武利尤单抗的挽救治疗

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
PubMed 文献 · J Clin Oncol · 2020-06-03

该回顾性研究纳入45例既往接受过抗PD-1通路治疗的转移性肾细胞癌患者,评估伊匹木单抗联合纳武利尤单抗的疗效与安全性。中位随访12个月,客观缓解率为20%,中位无进展生存期4个月。任意级别免疫相关不良事件发生率64%,3级免疫相关不良事件发生率13%。联合方案在既往免疫检查点抑制剂治疗后的患者中显示出抗肿瘤活性且毒性可接受。

要点

  • 既往抗PD-1治疗后转移性肾细胞癌,伊匹木单抗联合纳武利尤单抗客观缓解率20%。
  • 中位无进展生存期4个月,中位随访12个月。
  • 任意级别免疫相关不良事件64%,3级免疫相关不良事件13%。

核心结论

  • 伊匹木单抗联合纳武利尤单抗在既往接受过免疫检查点抑制剂治疗的转移性肾细胞癌患者中显示出抗肿瘤活性,且毒性可接受。

研究设计与样本

  • 回顾性研究,纳入45例既往接受过抗PD-1通路靶向治疗并后续接受伊匹木单抗联合纳武利尤单抗的转移性肾细胞癌患者。
  • 所有患者(100%)既往接受过靶向PD-1通路的免疫检查点抑制剂。
  • 中位年龄62岁(范围21-82岁)。

主要发现

  • 中位随访12个月时,伊匹木单抗联合纳武利尤单抗的客观缓解率为20%。
  • 伊匹木单抗联合纳武利尤单抗治疗期间的中位无进展生存期为4个月(范围0.8-19个月)。
  • 任意级别免疫相关不良事件记录于29例(64%)患者,3级免疫相关不良事件记录于6例(13%)患者。

临床怎么用

  • 对于既往接受过抗PD-1通路治疗的转移性肾细胞癌患者,可考虑伊匹木单抗联合纳武利尤单抗作为挽救治疗选择,需监测免疫相关不良事件。

局限性

  • 回顾性研究设计,样本量有限(45例),随访时间较短(中位12个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti-PD-1 pathway-targeted therapy. PATIENTS AND METHODS: Patients with metastatic RCC who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed. RESULTS: Forty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients. CONCLUSION: Ipilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gul A, Stewart TF, Mantia CM, et al. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. J Clin Oncol. 2020. PMID: 32491962. doi:10.1200/JCO.19.03315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。